Rockefeller Capital Management
JANX icon

Rockefeller Capital Management’s Janux Therapeutics JANX Stock Holding History

Rockefeller Capital Management’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.45K Sell
615
-178
-22% -$2.58K ﹤0.01% 4041
2026
Q1 		$11K Buy
793
+725
+1,066% +$9.94K ﹤0.01% 3958
2025
Q4 		$938 Buy
68
+61
+871% +$1.44K ﹤0.01% 4457
2025
Q3 		$171 Buy
+7
New +$170 ﹤0.01% 4354

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Rockefeller Capital Management's JANX Position: Q2 2026 in Review

Rockefeller Capital Management reduced its Janux Therapeutics (JANX) stake by 22% in Q2 2026, selling an estimated $2.58K and leaving 615 shares worth $9.45K. The position accounts for ﹤0.01% of the portfolio, ranked #4041.

Rockefeller Capital Management first reported a position in JANX in Q3 2025 and has held it in 4 quarters since. The position peaked at $11K in Q1 2026. 197 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

  • Rockefeller Capital Management held 615 shares of Janux Therapeutics worth $9.45K as of Q2 2026.
  • Rockefeller Capital Management sold 178 Janux Therapeutics shares in Q2 2026, an estimated $2.58K.
  • Janux Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #4041 holding.
  • Rockefeller Capital Management first reported a position in Janux Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Rockefeller Capital Management's Janux Therapeutics position peaked at $11K in Q1 2026.
  • 197 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.